Experimental trial on the effectiveness of IQOS compared to e-cigarettes and regular tobacco cigarettes

Similar documents
Int. J. Environ. Res. Public Health 2014, 11, ; doi: /ijerph OPEN ACCESS

Effectiveness of electronic cigarettes for smoking substitution

Effectiveness of electronic cigarettes for smoking substitution

Using the Balanced-Placebo Design for Parsing Nicotine Administration Effects

Use of e-cigarettes (vapourisers) among adults in Great Britain

E-cigarettes and personal vapourisers: current research and policy

Modelling the effects of user exposure to harmful emissions across the spectrum of nicotine delivery

Principal Investigator and Study Center: F. Nobuoka, MD Ageo Medical Clinic, 3133 Haraichi, Ageo City, Saitama , Japan

Nicotine Reduction: Harm Reduction not Prohibition

American Vaping Association

E cigarettes: how can research inform public policy?

Might Smoking Rates go up in Flames? Dr John Schoonbee, Chief Medical Officer, Swiss Re

E-Cigarettes: A Game Changer. Dr. Blake Brown Hugh C. Kiger Professor Agriculture and Resource Economics College of Agriculture & Life Sciences

Evaluation of Nicotine Pharmacokinetics and Subjective Effects following Use of a Novel Nicotine Aerosol System

Tobacco Heating System 2.2, A Candidate Modified Risk Tobacco Product: Cardiovascular Disease Risk Assessment

The Latest on Vaping Among U.S. Teens

Use of electronic cigarettes (vapourisers) among adults in Great Britain

Brief Report Randomized crossover trial of the acceptability of snus, nicotine gum, and Zonnic therapy for smoking reduction in heavy smokers

ELECTRONIC CIGARETTES WHAT S THE BOTTOM LINE?

Text 1: E-Cigarettes, the solution or another risk factor?

Survey to Measure the Effectiveness of Electronic Cigarettes - October 2012

Electronic cigarettes for smoking cessation

Heat-not-Burn Products: Scientific Assessment of Risk Reduction

Electronic Nicotine Delivery Systems: Patterns of Use and Disparities

Electronic Cigarettes: What we know so far

Analysis and Evaluation of a Cross-Sectional Study IEA World Congress of Epidemiology 20 th August Saitama, Japan

A combination of licensed medication and professional support is four times more likely to achieve a stop in smoking behaviour.

Electronic Nicotine Delivery Systems

There are many benefits to quitting for people with cancer even if the cancer diagnosis is not tobacco-related INCREASED

The State of Smoking 2018 Global Survey Findings and Insights. Monday, March 19, 2018

Pharmacotherapy Safety and Efficacy in Adolescent Smoking Cessation

The gateway theory. Pr Jean-François ETTER PhD (political science) E-cigarette Summit London, November 17, Competing interests: none

Low-Nitrosamine Dissolvable Tobacco Products Star Scientific, Inc. Part III Initiation and Cessation

Is Vaping a Valid Strategy for Smoking Cessation? Myths and Facts Jaspreet S. Brar. MD, PhD Community Care Behavioral Health Organization

Biomarker of Exposure Reductions Upon Switching for 5 Days from Cigarettes to a Carbon Heated Tobacco Product (CHTP 1.0)

Smoking, e-cigs and reduced risk products. Dr John Schoonbee, IMS November 2017

The importance of offering adult smokers a portfolio of potentially less harmful products

Helping Smokers to Quit in General Practice

Cardiovascular effects of nicotine vs. cigarette smoke

Commercial Ave., Northbrook, IL phone: (844)

Our Smokefree Trust. Information for patients and carers

Next Wave of Open System Device Consumers

Analysis of the Public's Perception on the Use of E- Cigarettes as an Alternative to Smoking

Product Standards for Reducing Nicotine in Cigarettes

Our Smokefree Trust. Information for patients and carers REVISED DRAFT. smoking and mental health - REVISED.indd 1 01/02/ :03:33

The State of Smoking 2018 Global Survey Findings and Insights. Monday, March 19, 2018

Helping Nurses Help Smokers Quit. Beth Allison, FNP BC OHSU Smoking Cessation Center & Tobacco Consult Service

Can E-cigarettes Help Curb the Smoking Epidemic in China?

Tobacco Control Tūranga Update Focus on reducing nicotine content in tobacco to help smokers quit

00:08 For decades our scientists have endeavoured to reduce the risks of tobacco use and continue to do so today. 00:15

Clear the Vapor: FILTERING FACTS FROM MYTHS ON VAPING, JUULING & CANNABIS

THE IMPORTANCE OF POINT OF SALE

Stop the Vape. Maria Hines RN, MSN. Denise Kneubuhler RN, MSN

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI.

Treating Tobacco Use:

E-Cigarettes: Current Perspective

Heated Tobacco Technology: Science, Behavior and Avoiding Unintended Consequences

Examining the Smoking and Vaping Behaviors and Preferences of Vape Shop Customers

USING APPS TO HELP SMOKERS QUIT

Non-Industry Voices on Tobacco Harm Reduction and Vaping Products

E-cigarettes: Evidence, perceptions and misconceptions. Martin Dockrell, Tobacco Control Programme Lead

Marketing a healthier choice: Exploring young people s perception of e-cigarettes

Electronic Cigarettes, Nicotine and Policy Implications

E-cigarettes in Europe : a consumer led revolution

Not ready to give up. Booklet 1

Assessment of the Tobacco Heating System (THS) 2.2, A Candidate Modified Risk Tobacco Product: From Concept to Early Clinical Data

The 5A's are practice guidelines on tobacco use prevention and cessation treatment (4):

E-cigarettes. Threat or opportunity?

Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt

Centre for Addictive Behaviours Research. Attitudes to tobacco and e- cigarettes, e-cig ads and ASMs

Lung Cancer Epidemiology & Prevention. A/Prof Fraser Brims

Our Smokefree Trust. Patient Information Leaflet. Easy Read

Rexall Ready-2-Quit. Continuous Care with Rexall

Tobacco Cessation, E- Cigarettes and Hookahs

12 Vaping Stats & Trends for the Informed E-Cig Retailer

Air Quality assessment during indoor use of the Tobacco Heating System 2.2

Global E-Cigarette Market- Industry Analysis & Outlook ( )

Discussion points on Bill S-5

Tobacco dependence: Implications for service provision

Chapter 14. Lessons. Bellringer

E.cigarettes. An alternative to a uniquely deadly product that kills one in two of its regular users? Paul Lambert Public Health, Leeds City Council

Correspondence should be addressed to Arit M. Harvanko;

A study to examine changes in exposure to cigarette smoke chemicals when a smoker switches to using a tobacco heating product. Part I: Study Design.

Smoking It s never too late to quit

Quality ID #404: Anesthesiology Smoking Abstinence National Quality Strategy Domain: Effective Clinical Care

PROJECT NEWS. Youth and Young Adult Vaping in Canada. Background. Methods. Key Findings

Fundamentals of Brief Cessation Counseling Approaches

Survey of U.S. Adult Cigarette Smokers

A proposed bridging approach for the assessment of novel tobacco products

E-Cigarettes and Vapes

Background. Description. Disclosure. Objectives. Types of ENDS. APNA 30th Annual Conference Session 4024: October 22, 2016.

Chapter 11 Tobacco Section 1: Tobacco Use

E-CIGARETTES CANCER INSIGHT WHAT YOU NEED TO KNOW ABOUT FOR PRACTICE NURSES. INSIDE: A3 poster to display in your practice.

Measure #404: Anesthesiology Smoking Abstinence National Quality Strategy Domain: Effective Clinical Care

E-CIGARETTES CANCER INSIGHT WHAT YOU NEED TO KNOW ABOUT. FOR GPs. INSIDE: A3 poster to display in your practice. October Created by Freepik

Nebraska Youth Tobacco Survey 2015/2017

Nicotine delivery from e-cigarettes part I: study designs for two pharmacokinetic studies.

E-Cigarettes and Health Care:

Satisfaction with smoking, and smoking reduction, during pre-quit treatment with nicotine patch or varenicline

Transcription:

Global Forum on Nicotine Rethinking Nicotine 2018 Experimental trial on the effectiveness of IQOS compared to e-cigarettes and regular tobacco cigarettes Effects on acute craving, withdrawal, positive and negative experiences Karolien Adriaens, MSc Dinska Van Gucht, PhD Frank Baeyens, PhD vs. vs.

Declaration of interest I have received no funding, nor have competing financial interests I have no ties with the e-cigarette industry, nor with the tobacco industry, nor with pharma companies My PhD research focuses on Tobacco Harm Reduction (THR) in general and e-cigarette based THR in particular 2

Introduction Proportion of current smokers in the EU remains stable since 2014: 26% (European Commission, 2017) E-cigarettes can be used as a THR tool Although it is not possible to precisely quantify the long-term health risks associated with e-cigarettes, the available data suggest that they are unlikely to exceed 5% of those associated with smoked tobacco products, and may well be substantially lower than this figure (Royal College of Physicians, 2016, p. 87) 3

Introduction In the EU, prevalence of e-cigarette users remains stable over the last years (European Commission, 2017): 15% at least tried e-cigarettes 2% are current vapers uptake remains relatively low 4

Introduction Not all smokers benefit from the use of e-cigarettes (McKeganey & Dickson, 2017): Among confirmed smokers, 59% has ever tried e-cigarettes Elements least liked about e-cigarettes were: Vaping experience Technology Chemical nature of liquids Complex technology 5

Introduction Recently, the tobacco industry developed alternative Reduced-Risk Products Tobacco Heating System (THS) (PMI, 2017) Heating instead of combustion Aerosol contains substantially reduced levels of toxicants Similar results regarding behavioral experiences compared to regular cigarettes However, little independent research, especially regarding behavioral experiences of THS use! 6

Methods Research questions What is the effect of using IQOS on exhaled carbon monoxide (eco) acute craving withdrawal symptoms subjective positive and negative experiences after smoking abstinence in regular smokers compared to using an e- cigarette or their regular tobacco cigarette? Which product (e-cigarette or IQOS) will be preferred by first-time users? 7

Methods Participants INCLUSION CRITERIA - Established, regular smoker for at least 3 years - Smoking 8 cigarettes per day or more - No intention to quit smoking within the following month - Willing / accepting to try out several less unhealthy alternatives EXCLUSION CRITERIA - Current use of any kind of smoking cessation therapy - Being a vaper now or in the past 6 months - Being a THS user now or in the past 6 months - Several medical conditions (e.g., diabetes, asthma, ) 8

Intake Day 1 Day 2 Day 3 Questionnaire: Demographics Smoking history FTCD eco measurement 0 min 5 min 10 min 12 hours smoking abstinence VAS cigarette + eco + QSU + MNWS 5 min smoking / vaping / using IQOS VAS cigarette + eco + QSU + MNWS + mceq VAS cigarette + eco 20 min VAS cigarette + eco 35 min VAS cigarette + eco N = 30 55 min VAS cigarette + eco + QSU + MNWS Add. Day 3: VAS product preference 9

Results Participants (n = 30) were: On average 22 years old Mostly male (67%) Almost all students (93%) Smoking on average 4 years Smoking currently on average 13 cigarettes per day (CPD) Low to moderate cigarette dependent (M_FTCD = 3.50) 10

Results eco levels ppm 10 9 8 7 6 5 4 3 2 1 0 Intake 0 min 5 min 10 min 20 min 35 min 55 min Time CIG E-CIG IQOS 11

Results acute cigarette craving 100 90 80 70 60 50 40 30 20 10 0 0 min 5 min 10 min 20 min 35 min 55 min Time 7 6 5 4 3 2 1 QSU-brief 0 min 5 min 55 min CIG E-CIG IQOS 12

Results product evaluation 7 6 5 4 3 2 1 Smoking satisfaction CIG E-CIG IQOS 7 6 5 4 3 2 1 Psychological reward CIG E-CIG IQOS 7 6 5 4 3 2 1 Aversion CIG E-CIG IQOS Smoking satisfaction Satisfying Taste good 5 Enjoy smoking 4 3 7 6 2 1 Enjoyment CIG E-CIG IQOS Psychological reward Calm down More awake Less irritable 4 Help concentrate 3 2 Reduce hunger 7 6 5 1 Craving reduction Dizziness Nauseous CIG E-CIG IQOS Aversion 13

Results product preference 100 80 60 40 20 0 IQOS 100 80 60 40 20 0 Trying out another 5 minutes Wanting to experiment 100 80 60 40 20 0 E-CIG IQOS E-CIG Willing to buy Using to quit smoking 100 40 20 0 IQOS E-CIG IQOS E-CIG 80 60 14

Conclusion In first-time users: No increase in eco level when vaping Significant increase in eco level when smoking and using IQOS, however, increase when using IQOS is minor, and comparable with previous research (PMI, 2017) Clear craving reduction for using IQOS, vaping and smoking, most pronounced for smoking Cigarette showed the best product evaluation, followed by IQOS and e- cigarette Relative low product preference for both IQOS and e-cigarette 15

Conclusion Results need to be seen in light of sample/products used First-time users One type of e-cigarette/liquid Main results in line with previous research Although similarities between using IQOS and smoking not that pronounced Long-term studies are needed to investigate the behavioral and psychological effects of long-term IQOS use compared to smoking and vaping 16

Thank you for your attention! Contact: Karolien Adriaens Dinska Van Gucht Frank Baeyens karolien.adriaens@kuleuven.be dinska.vangucht@thomasmore.be frank.baeyens@kuleuven.be 17